Skip to main
  1. Stocks
  2. ProMIS Neurosciences Inc
  3. Forecast
PMN

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences is supported by a differentiated scientific thesis: PMN310 is designed to selectively bind toxic amyloid-beta oligomers while sparing plaque, which could improve both efficacy and tolerability if the AβO hypothesis proves correct. The company’s PRECISE-AD Phase 1b interim data in 144 patients were encouraging, showing zero ARIA-E across all genotypes, placebo-like ARIA-H of 4.4%, and biomarker declines in pTau217 (-15%) and CSF MTBR-tau243 (-13.3%), while Phase 1a also showed dose-dependent exposure. Financially, the company reported a 2Q26 net loss of $11.7MM with $53.4MM in cash, and that balance was said to fund operations through 2027, supporting continued clinical execution ahead of the anticipated 1Q27 topline.

Bears say

ProMIS Neurosciences is viewed negatively because its lead program PMN310 remains a high-risk, unproven Alzheimer’s bet in a field where a closely related oligomer-targeting approach just failed in Ph2, raising doubts about whether selective Aβ oligomer binding can translate into meaningful clinical benefit. The company’s own risk profile is elevated by the uncertainty around the ongoing PRECISE-AD P1b study, where pooled biomarker analysis may dilute signal, while the cited DCF assumes only a 30% probability of approval, an 11.5% discount rate, and equity value of $255M with $100M in cash and 16.62M shares outstanding at the end of 2Q27. Beyond clinical risk, the stock faces financing and dilution pressure because later-stage Alzheimer’s development is large and costly, and PMN must still prove it can differentiate on efficacy and safety against approved, well-resourced competitors.

PMN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

PMN Analyst Forecast & Price Prediction

Get the latest PMN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PMN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 4 analysts, PMN has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


PMN Analyst Forecast & Price Prediction

Get the latest PMN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PMN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PMN stock data and trends